Protection Against Nephropathy in Diabetes with Atorvastatin

niversity of Manchester (UK)0 sites119 target enrollmentApril 21, 2008

Overview

Registry

who.int

Start Date

April 21, 2008

End Date

June 30, 2008

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

niversity of Manchester (UK)

•1\. Type 2 diabetes (defined according to the World Health Organization criteria) previously known to have proteinuria or microalbuminuria
•2\. Urinary albumin:creatinine ratio greater than 5 mg/mmol on two consecutive urine samples
•3\. Aged over 40
•4\. Capable of giving informed consent
•5\. Consent to inform General Practitioner of inclusion in study

•1\. Urinary protein output \>2g/24 hours
•2\. Serum creatinine \>\= 200 µmol/l
•3\. Blood pressure \>160/90 mmHg at randomisation
•4\. Women of child bearing potential
•5\. Serum cholesterol \>\= 7 mmol/l or fasting serum triglycerides \>\= 6 mmol/l at any visit
•6\. Taking \>10 mg of atorvastatin at screening
•7\. Untreated hypothyroidism
•8\. Hepatic dysfunction, transaminase \>2 times the upper limit of normal or alkaline phosphatase \>1\.5 times the upper limit of normal
•9\. Any other concomitant illness other than diabetes or its complication likely to effect outcome
•10\. Concomitant medication that may interact adversely with HMG\-CoA reductase inhibitors or ATII receptor antagonists